Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.52 |
| ▸ | MAPT | P10636 | 4/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | CRHBP | P24387 | 1/20 | 0.48 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | HCAR3 | P49019 | 4/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4280959 | 0.90 | KMT2A (0.56) | KMT2AMAPTALDH1A1RAB9APTGER4 | |
| SCHEMBL3762305 | 0.87 | HPGD (0.58) | KMT2AMAPTALDH1A1RAB9APTGER4 | |
| SCHEMBL4000202 | 0.86 | HCAR3 (0.54) | KMT2AMAPTALDH1A1RAB9APTGER4 | |
| SCHEMBL10048482 | 0.83 | MAPT (0.44) | KMT2AMAPTALDH1A1RAB9ANPC1 | |
| SCHEMBL3765728 | 0.82 | PTGER4 (0.64) | MAPTALDH1A1RAB9APTGER4NPC1 | |
| SCHEMBL8034115 | 0.82 | HCAR3 (0.53) | KMT2AMAPTALDH1A1RAB9APTGER4 | |
| SCHEMBL584707 | 0.81 | HTT (0.55) | KMT2AMAPTALDH1A1RAB9ANPC1 | |
| SCHEMBL15774461 | 0.80 | MAPT (0.71) | KMT2AMAPTALDH1A1RAB9APTGER4 | |
| SCHEMBL3915802 | 0.80 | MAPT (0.43) | KMT2AMAPTALDH1A1RAB9ANPC1 | |
| SCHEMBL3915803 | 0.80 | MAPT (0.43) | KMT2AMAPTALDH1A1RAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100305140-A1 | BENZIMIDAZOLE DERIVATIVES WHICH ARE TO BE USED AS ANTAGONIST FOR THE CB1-RECEPTOR | ASTRAZENECA AB (SE) | 2010-12-02 | — | — | US | disclosed |
| US-20100305140-A1 | BENZIMIDAZOLE DERIVATIVES WHICH ARE TO BE USED AS ANTAGONIST FOR THE CB1-RECEPTOR | ASTRAZENECA AB (SE) | 2010-12-02 | — | — | US | disclosed |
| US-20100305140-A1 | BENZIMIDAZOLE DERIVATIVES WHICH ARE TO BE USED AS ANTAGONIST FOR THE CB1-RECEPTOR | ASTRAZENECA AB (SE) | 2010-12-02 | — | — | US | disclosed |
| US-7517898-B2 | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof | ASTRAZENECA AB (SE) | 2009-04-14 | — | — | US | disclosed |
| US-7517898-B2 | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof | ASTRAZENECA AB (SE) | 2009-04-14 | — | — | US | disclosed |
| EP-2035409-A1 | BENZIMIDAZOLE DERIVATIVES WHICH ARE TO BE USED AS ANATGONIST FOR THE CB1-RECEPTOR | AstraZeneca AB (SE) | 2009-03-18 | — | — | EP | disclosed |
| WO-2007145563-A1 | BENZIMIDAZOLE DERIVATIVES WHICH ARE TO BE USED AS ANTAGONIST FOR THE CB1-RECEPTOR | ASTRAZENECA AB (SE) | 2007-12-21 | — | — | WO | disclosed |
| WO-2007145563-A1 | BENZIMIDAZOLE DERIVATIVES WHICH ARE TO BE USED AS ANTAGONIST FOR THE CB1-RECEPTOR | ASTRAZENECA AB (SE) | 2007-12-21 | — | — | WO | disclosed |
| US-20070060583-A1 | Benzimidazole derivatives, compositions containing them, preparation therof and uses thereof | ASTRAZENECA AB (SE) | 2007-03-15 | — | — | US | disclosed |
| US-20070060583-A1 | Benzimidazole derivatives, compositions containing them, preparation therof and uses thereof | ASTRAZENECA AB (SE) | 2007-03-15 | — | — | US | disclosed |
| EP-1636193-A1 | BENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM, PREPARATION THEREOF AND USES THEREOF | AstraZeneca AB (SE) | 2006-03-22 | — | — | EP | disclosed |
| WO-2004108688-A1 | BENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM, PREPARATION THEREOF AND USES THEREOF | ASTRAZENECA AB (SE) | 2004-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305140-A1 | BENZIMIDAZOLE DERIVATIVES WHICH ARE TO BE USED AS ANTAGONIST FOR THE CB1-RECEPTOR | CNR1, CNR2, CCKAR | KMT2A 1825/4885MAPT 4180/4885ALDH1A1 1779/4885 |
| US-20070060583-A1 | Benzimidazole derivatives, compositions containing them, preparation therof and uses thereof | BTF3, TYMS, F3 | KMT2A 2858/4885MAPT 2820/4885ALDH1A1 1603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.